Video Experimental Relacionado

Updated: Feb 20, 2026

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Farmacoterapia para el manejo de la obesidad: énfasis en el papel de los agonistas del receptor GLP-1

Bruce A Warden¹, Paul Barton Duell², John D Bucheit³

¹Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA (Drs Warden, Duell, and Purnell); General Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA (Dr Warden).

Journal of clinical lipidology

|February 18, 2026

Abstracto

Background:

Obesity is a chronic disease, rooted in genetic predisposition and homoeostatic counter-regulatory adaptive and hormonal responses, with escalating prevalence rates and numerous associated health consequences.

Sources Of Material:

Historically, interventions beyond lifestyle for the treatment of obesity have been underutilized, stigmatized, and held to different standards of validation compared to treatments for other chronic cardiovascular risk factors.

Abstract Of Findings:

Contemporary management of obesity requires implementation of lifestyle modifications, employment of pharmacotherapy, and in more severe cases, surgical intervention. The purpose of this manuscript is to review obesity medication (OM) use in adults, with an emphasis on glucagon-like peptide-1 receptor agonists (GLP-1 RA) and GLP-1 RA/glucose- dependent insulinotropic polypeptide (GIP) dual receptor agonists, focusing on patient selection, strategies for initiation and titration of these medications in clinical practice, emerging evidence of benefit and potential risk, as well as medication access and cost considerations.

Conclusion:

GLP-1 RAs have emerged as a highly effective, safe, and well tolerated pharmacotherapy option for the management of obesity, possessing a myriad disease-modifying outcomes and capable of curtailing the rapid rise in obesity and related complications.

Palabras clave:

Obesidad Agonistas del receptor de péptido similar al glucagón tipo 1 Manejo de la obesidad Medicamento para la obesidad Farmacoterapia

Más Videos Relacionados

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Videos de Conceptos Relacionados

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...